Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cannabis and schizophrenia: a Real-World look at the dual effects

NCT ID NCT07309159

Knowledge-focused Sponsor: Centre Hospitalier Charles Perrens, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 120 people with schizophrenia who use cannabis, using mobile phone surveys and thinking tasks to track symptoms in real time. The goal is to understand how cannabis may both worsen positive symptoms (like hallucinations) and reduce negative symptoms (like lack of motivation). The findings could help shape better care for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabis
What this could lead to
If successful, this study could clarify how cannabis affects schizophrenia symptoms, potentially guiding better management strategies.
What could go wrong
This is an early-phase observational study, not a treatment trial. Results may not lead to direct clinical changes, and cannabis use carries known risks for mental health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * DSM-5 diagnosis of schizophrenia or schizo-affective disorder with the following clinical features: * Clinically stable and in the residual (non-acute) phase of illness, * No change in antipsychotic treatment for at least 1 month, * Outpatient, ambulatory care, * No uncontrolled positive symptoms (assessed using PANSS) * Patients able to use a mobile phone. * Capacity and willingness to give informed consent. * Must be able to read, speak, and understand French * Patients subscribing to the French national medical insurance. * Patients under "curatelle" (partial guardianship) are eligible Exclusion Criteria: Patient under "tutelle" (full legal guardianship). * Psychiatric comorbidities: autism, bipolar disorder. * Current criteria for any other substance use disorder except for nicotine use disorder. * Any medical condition hindering the study and/or use of the smartphone application. * Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….). * Pregnant or breastfeeding woman. * Patients who are not proficient in French. * Subject included in clinical and/or therapeutic experimentation in progress.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizo affective disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.